Ibrutinib is the first-in-class Bruton Tyrosine Kinase (BTK) inhibitor which acts switching off BTK-dependent BCR signaling and is currently approved for relapsed/refractory (R/R) MCL. This evidence concerns the gene BCR and mantle cell lymphoma.